-
Thematic Analysis
NewPsychedelics Therapeutics Development and Trends, 2024
This report provides a summary of the current and future state of the psychedelic therapeutic sector, offering a high-level analysis of key trends and developments within the industry, including regulatory, clinical, and market dynamics. The report identifies the broader changes within the evolving psychedelic industry, facilitating informed decision-making for relevant sectors.
-
Sector Analysis
NewResistant Hypertension (RH) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Resistant Hypertension (RH) Marketed and Pipeline Drugs Report Overview Resistant Hypertension (RH) refers to high blood pressure (BP) that is above the target level in a patient. This occurs even when they are taking three different classes of antihypertensive medications concurrently. These medication classes typically include diuretics, long-acting calcium channel blockers, and renin-angiotensin system blockers (ACEs or ARBs). The Resistant Hypertension (RH) marketed, and pipeline drugs research report includes an assessment of the disease epidemiology, leading marketed products with sales...
-
Sector Analysis
NewRetinitis Pigmentosa (RP) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Retinitis Pigmentosa (RP) Marketed and Pipeline Drugs Report Overview Retinitis pigmentosa (RP) is a cluster of rare eye conditions. One of these conditions causes degeneration of the retina, the light-sensitive layer at the back of the eye. This degeneration results in a progressive loss of vision. Retinitis pigmentosa is an inherited genetic disorder. Most people have progressive vision loss over time, with symptoms usually starting in childhood. While there isn't a cure at this time, people can maximize their residual...
-
Sector Analysis
NewAntibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products, Opportunities and Challenges
Antibody-Drug Conjugates Market Report Overview An Antibody-Drug Conjugates (ADC) drug consists of monoclonal antibodies conjugated to a payload via a linker, for the precise targeting of antigen-positive cancer cells. ADCs are developed to target protein receptors with high expression such as HER2, TROP-2, CD22, and others. There are two cytotoxic payload types predominantly used in ADCs including microtubule inhibitors, and the more potent DNA-damaging payloads such as topoisomerase I inhibitors. The ADC market research report will aid clients in gaining...
-
Sector Analysis
NewPeripheral Artery Disease (PAD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Peripheral Artery Disease Marketed and Pipeline Drugs Report Overview PAD is an atherosclerotic disease in which the formation of atherosclerotic plaque causes narrowing of the arteries and poor perfusion to the limbs. This can progress to arterial occlusion and chronic limb-threatening ischemia (CLTI). PAD can happen in any blood vessel, but it is more common in the legs than the arms. Key Mechanisms of Action (Marketed) · Receptor Agonist · Enzyme Inhibitor · Biological Factor Activator · Ligand Inhibitor · ...
-
Sector Analysis
NewFuchs Endothelial Corneal Dystrophy (FECD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Fuchs Endothelial Corneal Dystrophy Marketed and Pipeline Drugs Report Overview Fuchs Endothelial Corneal Dystrophy (FECD) is a bilateral, slowly progressive, often asymmetric corneal disease. FECD is a sporadic or autosomal dominant dystrophy involving the endothelial layer of the cornea. Key Mechanisms of Action (Pipeline) · Enzyme Inhibitor · Receptor Agonist · Protein and Peptide Inhibitor · Transporter Inhibitor Key Molecule Types (Pipeline) · Small Molecule · Biologic Key Routes of Administration (Pipeline) · Topical · Oral · Injection Top Sponsors...
-
Sector Analysis
NewCell and Gene Therapies in Ophthalmology – Disease Overview, Treatment Options and Future Market Assessment
Cell and Gene Therapies in Ophthalmology Market Report Overview The Cell and Gene Therapies (CGT) in ophthalmology market was $46 million in 2023. The market will experience moderate growth during the forecast period with gene therapies targeting Leber congenital amaurosis (LCA) and retinitis likely to be the primary drivers of the CGT market in the ophthalmology space. The CGT in ophthalmology market research report will aid clients in gaining insight into the competitive landscape of leading CGT agents in ophthalmology...
-
Thematic Analysis
NewGeneric Drugs – Physician Perspective – Thematic Intelligence
Reasons to buy the ‘Generic Drugs – Physician Perspective’ thematic intelligence report: Assess healthcare professionals’ attitudes towards generic drugs prescription. Better understand the barriers to the production and uptake of generic medicines. Capture physicians’ opinions on generics substitution. Better understand patients’ preferences. Assess past and future generics uptake. Gain a better understanding of cost consideration when prescribing drugs. Explore the differences across markets. How is our ‘Generic Drugs – Physician Perspective’ report unique from other reports in the market? This...
-
Product Insights
NewClinical Trials Scorecard for Investigations in 2023
This report provides an overview of global clinical trials with a start date between January 1, 2023, and December 31, 2023.
-
Product Insights
NewBorderline Personality Disorder (BPD) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Borderline Personality Disorder (BPD) Clinical Trial Report Overview A total of 71 borderline personality disorder (BPD) clinical trials were conducted as of March 2024. The borderline personality disorder (BPD) clinical trial report provides a comprehensive understanding of the borderline personality disorder (BPD) clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with...
Testimonial
Your Drugs database is great, you can find all the information you want such as sales forecasts, countries, diseases, dates, clinical trials, and patent expiration. We are using this information to research the leading competitive products in our current project. In addition, we analyze the profiles of the leading products and use this information to set the differentiation profile of our own products and clarify our positioning. In terms of business forecasts, we are able to provide more objective figures by using the Drug Forecast and Market Analysis report series. The analysis of product share by disease (series of Drug Forecast and Market Analysis reports) is used for business feasibility assessment.”
The ability to evaluate or provide information on PJs in R&D from both product and disease perspectives (it is difficult to find a database that can be used comprehensively for both), stands GlobalData out from other providers. The release of new functions such as Likelihood of approval (LoA) analysis, which was something I wanted but did not exist, shows that GlobalData have done a good job of researching the industry and developing services from the customer’s perspective which is another positive.
GlobalData’s COVID-19 Bulletin, which is sent out several times a week, provides the latest information on COVID-19 related vaccines and therapeutics and is used as background information.
“GlobalData provides extensive and comprehensive Pharma and Biotech data along with spectacular customer support. I use their drug, trial and company data on a daily basis to support our sales and marketing efforts.”
“As a global biopharma R&D strategy consultancy, we use the GlobalData Pharma Intelligence platform across a broad spectrum of topics, it provides all key data in one place”